Safety and usage of atypical antipsychotic medicines in children: A nationwide prospective cohort study

Drug Safety

Volumn 30, Issue 7, 2007, Pages 569-579

  Harrison Woolrych, Mira ^a   Garcia Quiroga, Juan ^a   Ashton, Janelle ^a   Herbison, Peter ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; CLOZAPINE; METHYLPHENIDATE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADJUSTMENT DISORDER; ADOLESCENT; AGGRESSION; ANXIETY DISORDER; APPETITE; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BIPOLAR DISORDER; BLEPHAROSPASM; BLOOD PRESSURE; BODY WEIGHT; CHICKENPOX; CHILD; CLINICAL ASSESSMENT; COGNITIVE DEFECT; COHORT ANALYSIS; CONDUCT DISORDER; CONSTIPATION; DELUSION; DENTAL CARIES; DEPRESSION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; DYSTONIA; EPILEPSY; EPISTAXIS; FACIAL EXPRESSION; FEMALE; HERPES; HUMAN; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; INCIDENCE; INFECTION; INFECTIOUS DIARRHEA; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MANIA; MEDICAL RECORD; MENTAL DEFICIENCY; MOOD DISORDER; MUSCLE CRAMP; NOCTURNAL ENURESIS; OBSERVATIONAL STUDY; OTITIS MEDIA; PATIENT COMPLIANCE; PATIENT MONITORING; PEDIATRICS; POLYDIPSIA; POLYURIA; POSTMARKETING SURVEILLANCE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; PTOSIS; QUESTIONNAIRE; SCHIZOPHRENIA; SIDE EFFECT; SKIN INFECTION; SLEEP DISORDER; SOMNOLENCE; TIC; TOOTH ABSCESS; TORSION DYSTONIA; TORTICOLLIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WORM INFECTION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; CLOZAPINE; COHORT STUDIES; DIBENZOTHIAZEPINES; DRUG UTILIZATION; FEMALE; HUMANS; MALE; NEW ZEALAND; RISPERIDONE;

EID: 34447133528     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730070-00002     Document Type: Article

References (27)

1. Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006; 63 (6): 679-85
2. Curtis LH, Masselink LE, Ostbye T, et al. Prevalence of atypical antipsychotic drug use among commercially insured youths in the United States. Arch Pediatr Adolesc Med 2005; 159 (4): 362-6
3. Cheng-Shannon J, McGough JJ, Pataki C, et al. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14 (3): 372-94
4. Greenhill LL, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 2003; 42 (6): 651-5
5. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf 1998; 7 (2): 79-90
6. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In: Mann R, Andrews E, editors. Pharmacovigilance. Second ed. Chichester: John Wiley & Sons, 2007: 317-32
7. Coulter DM. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf 2001; 10: 663-7
8. Edwards I, Olsson S. WHO Programme - Global monitoring. In: Mann R, Andrews E, editors. Pharmacovigilance. First ed. Chichester: John Wiley & Sons, 2002
9. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA 1975; 234 (12): 1236-41
10. Patel NC, Crismon ML, Hoagwood K, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 2005; 44 (6): 548-56
11. Janssen-Cilag. Risperidone data sheet [online]. Available from URL: http://www.medsafe.govt.nz/profs/Datasheet/DSForm.asp [Accessed 2007 Jun 6]
12. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159 (8): 1337-46
13. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004; 161 (4): 677-84
14. Croonenberghs J, Fegert JM, Findling RL, et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005; 44 (1): 64-72
15. Reyes M, Croonenberghs J, Augustyns I, et al. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006; 16 (3): 260-72
16. Patel NC, Crismon ML, Shafer A. Diagnoses and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 2006; 40 (2): 205-11
17. Clark DWJ, Harrison-Woolrych M. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Current Drug Safety 2006; 1 (2): 169-78
18. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41 (9): 1026-36
19. Turgay A, Binder C, Snyder R, et al. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002; 110 (3): e34
20. Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs 2004; 6 (1): 33-44
21. NZHIS. Selected morbidity data for publicly funded hospitals 2001/02 [online]. Available from URL: http://www.nzhis.govt.nz/publications/morbidity01- 02.pdf [Accessed 2007 Apr 30]
22. Broadbent JM, Ayers KM, Thomson WM. Is attention-deficit hyperactivity disorder a risk factor for dental caries? A case-control study. Caries Res 2004; 38 (1): 29-33
23. Selva KA, Scott SM. Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 2001; 138 (6): 936-8
24. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23 (6): 735-44
25. Koller E, Malozowski S, Doraiswamy PM. Atypical antipsychotic drugs and hyperglycemia in adolescents. JAMA 2001; 286 (20): 2547-8
26. Margolese HC, Annable L, Dion Y. Depression and dysphoria in adult and adolescent patients with Tourette's disorder treated with risperidone. J Clin Psychiatry 2002; 63 (11): 1040-4
27. Comings BG, Comings DE. A controlled study of Tourette syndrome: V. Depression and mania. Am J Hum Genet 1987; 41 (5): 804-21